The company's latest launch in this field, Alyftrek, can be taken once daily -- versus twice a day for the one before that.

Vertex Pharmaceuticals' revenue from its cystic fibrosis franchise grew 10% quarter-on-quarter. Click here to see why VRTX ...

Sionna’s medicine didn’t have a meaningful additive impact when combined with Vertex’s top-selling Trikafta, surprising ...

Cystic fibrosis investors came to learn a harsh lesson on August 10 about how concentrated a market can be: Sionna Therapeutics, Inc. (NASDAQ:SION) shares fell more than 90% following a key trial ...

Sionna Therapeutics has axed a cystic fibrosis add-on program after flunking a phase 2 trial, eliminating a would-be challenger to Vertex Pharmaceuticals’ empire. The biotech plans to “take actions to ...

Jason is a general assignment reporter, with particular focus on genetic medicine and rare disease. Confidential tips can be sent on Signal at JasonMast.77. Sionna Therapeutics said Monday that its ...

Vertex Pharmaceuticals shares rose after rival Sionna Therapeutics said a midstage trial of its cystic-fibrosis treatment failed to meet its primary endpoint, sending Sionna shares tumbling. Shares of ...

Vertex stock surged Monday after its competitor, Sionna Therapeutics, missed the mark for its highly anticipated cystic ...

Good day, and welcome to the Vertex Pharmaceuticals Second Quarter 2026 Earnings Call. [Operator Instructions] Please note this event is being recorded. I would now like to turn the conference over to ...

Vertex Pharmaceuticals on Monday raised the upper end of its annual revenue forecast, banking on robust demand for its cystic ​fibrosis treatments.

Ed’s stories explore prescription drug pricing, affordability and access, as well issues surrounding patents, litigation, and legislation. He is also the author of the morning Pharmalittle newsletter ...